ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing
ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing - Phase 1 clinical study recruitment in healthy volunteers is expected to start in Q1 2021 - - - Recently completed Phase 1 trial in oncology patients demonstrated good safety profile - HOUSTON--(BUSINESS WIRE)--ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-...
United States Benjamin Cowen Immunomet Therapeutics Inc Drug Administration Immunomet Therapeutics Investigational New Drug
Source: ibtimes.com.au